TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
First Tracks Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$36.28+1.82 (+5.28%)
Close on Oct 19, 2026
- Market cap
- $1.27B
- P/E (TTM)
- –
- Dividend yield
- –
First Tracks Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | First Tracks Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $1.30B | $166.30M |
| Enterprise Value | $1.13B | $88.19M |
| PB Ratio | 7.68 | 2.03 |
| P/TBV Ratio | 7.68 | 2.29 |
Balance sheet
| Measure | First Tracks Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $168.02M | $61.43M |
| Net Cash (Debt) | $168.02M | $15.35M |
| Net Cash Per Share | $4.70 | $0.66 |
| Equity (Book Value) | $168.80M | $49.09M |
| Book Value Per Share | $4.72 | $1.37 |
| Tangible Book Value | $168.80M | $23.52M |
| Working Capital | $165.30M | $76.81M |
Financial position
| Measure | First Tracks Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 14.28 | 3.34 |
| Quick Ratio | 13.50 | 2.44 |
Shares
| Measure | First Tracks Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 35,730,800 | 58,127,000 |
| Float | 35,056,800 | 49,136,700 |
| Shares Held by Insiders | 1.89% | 11.6% |
| Shares Held by Institutions | 92.0% | 59.4% |
Scores
| Measure | First Tracks Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 55.12 | -0.22 |
Calculated by StockData from First Tracks Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.